{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T23:00:49Z","timestamp":1791414049268,"version":"4.3.3"},"reference-count":34,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","nmd-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuromuscular Disorders"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1016\/j.nmd.2023.02.013","type":"journal-article","created":{"date-parts":[[2023,3,4]],"date-time":"2023-03-04T01:58:24Z","timestamp":1677895104000},"page":"358-366","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":39,"title":["Clinical characteristics and prognosis of very late-onset myasthenia gravis in China"],"prefix":"10.1016","volume":"33","author":[{"given":"Yong-Lan","family":"Tang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhe","family":"Ruan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong-Jing","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huan-Huan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhu-Yi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7546-8017","authenticated-orcid":false,"given":"Ting","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"26","key":"10.1016\/j.nmd.2023.02.013_bib0001","doi-asserted-by":"crossref","first-page":"2570","DOI":"10.1056\/NEJMra1602678","volume":"375","author":"Gravis","year":"2016","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.nmd.2023.02.013_bib0002","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/S1474-4422(15)00145-3","article-title":"Myasthenia gravis: subgroup classification and therapeutic strategies","volume":"14","author":"Gilhus","year":"2015","journal-title":"Lancet Neurol"},{"issue":"5","key":"10.1016\/j.nmd.2023.02.013_bib0003","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1038\/nrneurol.2016.44","article-title":"Myasthenia gravis - autoantibody characteristics and their implications for therapy","volume":"12","author":"Gilhus","year":"2016","journal-title":"Nat Rev Neurol"},{"issue":"3","key":"10.1016\/j.nmd.2023.02.013_bib0004","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1111\/cei.12217","article-title":"Myasthenia gravis: an update for the clinician","volume":"175","author":"Sieb","year":"2014","journal-title":"Clin Exp Immunol"},{"issue":"10","key":"10.1016\/j.nmd.2023.02.013_bib0005","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1136\/jnnp.2008.152637","article-title":"Increasing incidence of elderly onset patients with myasthenia gravis in a local area of Japan","volume":"80","author":"Matsui","year":"2009","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"1-2","key":"10.1016\/j.nmd.2023.02.013_bib0006","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.jns.2011.03.004","article-title":"Characteristics of myasthenia gravis according to onset-age: Japanese nationwide survey","volume":"305","author":"Murai","year":"2011","journal-title":"J Neurol Sci"},{"issue":"5","key":"10.1016\/j.nmd.2023.02.013_bib0007","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/S1474-4422(09)70063-8","article-title":"Autoimmune myasthenia gravis: emerging clinical and biological heterogeneity","volume":"8","author":"Meriggioli","year":"2009","journal-title":"Lancet Neurol"},{"issue":"8","key":"10.1016\/j.nmd.2023.02.013_bib0008","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1136\/jnnp.74.8.1105","article-title":"Evidence of underdiagnosis of myasthenia gravis in older people","volume":"74","author":"Vincent","year":"2003","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"5","key":"10.1016\/j.nmd.2023.02.013_bib0009","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1002\/mus.23964","article-title":"Late-onset myasthenia gravis: a review when incidence in older adults keeps increasing","volume":"48","author":"Alkhawajah","year":"2013","journal-title":"Muscle Nerve"},{"issue":"11","key":"10.1016\/j.nmd.2023.02.013_bib0010","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1111\/j.1532-5415.2000.tb02635.x","article-title":"Clinical characteristics and prognosis of myasthenia gravis in older people","volume":"48","author":"Evoli","year":"2000","journal-title":"J Am Geriatr Soc"},{"issue":"11","key":"10.1016\/j.nmd.2023.02.013_bib0011","doi-asserted-by":"crossref","first-page":"e1171","DOI":"10.1212\/WNL.0000000000008903","article-title":"Clinical and therapeutic features of myasthenia gravis in adults based on age at onset","volume":"94","author":"Cort\u00e9s-Vicente","year":"2020","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.nmd.2023.02.013_bib0012","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/0022-510X(83)90095-3","article-title":"Anti-acetylcholine receptor antibodies in myasthenia gravis. Part 1. relation to clinical parameters in 250 patients","volume":"58","author":"Limburg","year":"1983","journal-title":"J Neurol Sci"},{"issue":"5","key":"10.1016\/j.nmd.2023.02.013_bib0013","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1212\/WNL.40.5.786","article-title":"The relationship of age to outcome in myasthenia gravis","volume":"40","author":"Donaldson","year":"1990","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/j.nmd.2023.02.013_bib0014","doi-asserted-by":"crossref","first-page":"2775","DOI":"10.1007\/s10072-021-05599-z","article-title":"Characteristics of myasthenia gravis in elderly patients: a retrospective study","volume":"43","author":"Li","year":"2022","journal-title":"Neurol Sci"},{"issue":"4","key":"10.1016\/j.nmd.2023.02.013_bib0015","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1002\/mus.27369","article-title":"Clinical profile and impact of comorbidities in patients with very-late-onset myasthenia gravis","volume":"64","author":"Vijayan","year":"2021","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.nmd.2023.02.013_bib0016","article-title":"Incidence, mortality, and economic burden of myasthenia gravis in China: a nationwide population-based study","volume":"5","author":"Chen","year":"2020","journal-title":"Lancet Reg Health West Pac"},{"issue":"6","key":"10.1016\/j.nmd.2023.02.013_bib0017","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1002\/mus.26695","article-title":"Cross-sectional analysis of the myasthenia gravis patient registry: disability and treatment","volume":"60","author":"Cutter","year":"2019","journal-title":"Muscle Nerve"},{"issue":"1","key":"10.1016\/j.nmd.2023.02.013_bib0018","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/S0003-4975(00)01595-2","article-title":"Myasthenia gravis: recommendations for clinical research standards. task force of the medical scientific advisory board of the myasthenia gravis foundation of America","volume":"70","author":"Jaretzki","year":"2000","journal-title":"Ann Thorac Surg"},{"issue":"1-2","key":"10.1016\/j.nmd.2023.02.013_bib0019","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.jneuroim.2010.10.023","article-title":"Clinical and immunological differences between early and late-onset myasthenia gravis in Japan","volume":"230","author":"Suzuki","year":"2011","journal-title":"J Neuroimmunol"},{"issue":"1","key":"10.1016\/j.nmd.2023.02.013_bib0020","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1080\/01616412.2018.1525121","article-title":"Clinical differences of early and late-onset myasthenia gravis in 985 patients","volume":"41","author":"Fan","year":"2019","journal-title":"Neurol Res"},{"key":"10.1016\/j.nmd.2023.02.013_bib0021","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/1471-2377-10-46","article-title":"A systematic review of population based epidemiological studies in myasthenia gravis","volume":"10","author":"Carr","year":"2010","journal-title":"BMC Neurol"},{"issue":"5","key":"10.1016\/j.nmd.2023.02.013_bib0022","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1007\/s00415-017-8478-z","article-title":"Juvenile-onset myasthenia gravis: autoantibody status, clinical characteristics and genetic polymorphisms","volume":"264","author":"Hong","year":"2017","journal-title":"J Neurol"},{"issue":"2","key":"10.1016\/j.nmd.2023.02.013_bib0023","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1172\/JCI114724","article-title":"Hla antigens in Japanese patients with myasthenia gravis","volume":"86","author":"Matsuki","year":"1990","journal-title":"J Clin Invest"},{"issue":"8822","key":"10.1016\/j.nmd.2023.02.013_bib0024","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/0140-6736(92)92343-E","article-title":"Distortion of Hla gene transmission in childhood-onset myasthenia gravis","volume":"340","author":"Matsuki","year":"1992","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.nmd.2023.02.013_bib0025","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.ejpn.2017.04.003","article-title":"Juvenile myasthenia gravis in Norway: clinical characteristics, treatment, and long-term outcome in a nationwide population-based cohort","volume":"21","author":"Popperud","year":"2017","journal-title":"Eur J Paediatr Neurol"},{"issue":"11","key":"10.1016\/j.nmd.2023.02.013_bib0026","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1111\/j.1468-1331.2012.03698.x","article-title":"A national epidemiological study of myasthenia gravis in Australia","volume":"19","author":"Gattellari","year":"2012","journal-title":"Eur J Neurol"},{"issue":"1-2","key":"10.1016\/j.nmd.2023.02.013_bib0027","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1159\/000500268","article-title":"A prospective study of the incidence of myasthenia gravis in the east midlands of England","volume":"53","author":"Maddison","year":"2019","journal-title":"Neuroepidemiology"},{"issue":"1","key":"10.1016\/j.nmd.2023.02.013_bib0028","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1111\/ane.13239","article-title":"Incidence of Achr Ab-positive myasthenia gravis in israel: a population-based study","volume":"142","author":"Lotan","year":"2020","journal-title":"Acta Neurol Scand"},{"issue":"3","key":"10.1016\/j.nmd.2023.02.013_bib0029","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1002\/mus.25068","article-title":"Epidemiology of myasthenia gravis in northern portugal: frequency estimates and clinical epidemiological distribution of cases","volume":"54","author":"Santos","year":"2016","journal-title":"Muscle Nerve"},{"issue":"4","key":"10.1016\/j.nmd.2023.02.013_bib0030","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1002\/mus.24348","article-title":"Incidence of acetylcholine receptor-antibody-positive myasthenia gravis in South Africa","volume":"51","author":"Mombaur","year":"2015","journal-title":"Muscle Nerve"},{"issue":"4","key":"10.1016\/j.nmd.2023.02.013_bib0031","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1159\/000431036","article-title":"Geographical distribution of myasthenia gravis in Northern Europe\u2013results from a population-based study from two countries","volume":"44","author":"Boldingh","year":"2015","journal-title":"Neuroepidemiology"},{"issue":"10","key":"10.1016\/j.nmd.2023.02.013_bib0032","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1007\/s00415-012-6478-6","article-title":"Characteristics of late-onset myasthenia gravis","volume":"259","author":"Zivkovi\u0107","year":"2012","journal-title":"J Neurol"},{"key":"10.1016\/j.nmd.2023.02.013_bib0033","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1111\/ane.12233","article-title":"Myasthenia gravis epidemiology in a national cohort; combining multiple disease registries","volume":"198","author":"Andersen","year":"2014","journal-title":"Acta Neurol Scand Suppl"},{"issue":"6","key":"10.1016\/j.nmd.2023.02.013_bib0034","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1038\/ncpneuro0810","article-title":"Steroids and immunosuppressant drugs in myasthenia gravis","volume":"4","author":"Sathasivam","year":"2008","journal-title":"Nat Clin Pract Neurol"}],"container-title":["Neuromuscular Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960896623000640?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960896623000640?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T08:13:14Z","timestamp":1760775194000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960896623000640"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4]]},"references-count":34,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["S0960896623000640"],"URL":"https:\/\/doi.org\/10.1016\/j.nmd.2023.02.013","relation":{},"ISSN":["0960-8966"],"issn-type":[{"value":"0960-8966","type":"print"}],"subject":[],"published":{"date-parts":[[2023,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical characteristics and prognosis of very late-onset myasthenia gravis in China","name":"articletitle","label":"Article Title"},{"value":"Neuromuscular Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nmd.2023.02.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}